Resources from the same session
Scheduled use of CEA and CT follow-up to detect recurrence of colorectal cancer: 6-12 year results from the FACS randomised controlled trial
Presenter: Sian Pugh
Session: Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?
Presenter: Jemma Bhoday
Session: Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Slides
Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study
Presenter: Eric Van Cutsem
Session: Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Slides
Invited discussant abstracts 454O, 455O and LBA20
Presenter: Volker Heinemann
Session: Gastrointestinal tumours, colorectal 1
Resources:
Slides
Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)
Presenter: Ryan Corcoran
Session: Gastrointestinal tumours, colorectal 1
Resources:
Abstract
Slides
A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial
Presenter: Derek Jonker
Session: Gastrointestinal tumours, colorectal 1
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.